You are here

SCARAB GENOMICS, LLC

Company Information
Address
1202 Ann St
MADISON, WI 53713-2410
United States


http://www.scarabgenomics.com

Information

UEI: S4XQJDL7DN15

# of Employees: 14


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Toxoid adjuvant CRM197 production in a stable reduced genome E. coli strain

    Amount: $140,925.00

    DESCRIPTION (provided by applicant): Scarab Genomics has developed valuable reduced-genome strains of Escherichia coli in which multiple deletions remove from the genome much unwanted and all potentia ...

    SBIRPhase I2012Department of Health and Human Services National Institutes of Health
  2. A protease-deficient, low mutation rate E. coli for biotherapeutics production

    Amount: $155,032.00

    DESCRIPTION (provided by applicant): Biotherapeutics is a fast-growth sector in the pharmaceutical market with monoclonal antibodies accounting for almost 50% of the 100 billion USD spent each year on ...

    SBIRPhase I2012Department of Health and Human Services National Institutes of Health
  3. Innate Immune Protection by Clean Genome E. coli

    Amount: $1,748,517.00

    DESCRIPTION (provided by applicant): Complications arising from pathogen infection incur a tremendous societal cost both in morbidity and mortality (as high as 50-60%), as well as in care and treatmen ...

    SBIRPhase II2011Department of Health and Human Services National Institutes of Health
  4. Uniform length DNA for paired end nextgen sequencing via in vitro packaging

    Amount: $127,387.00

    DESCRIPTION (provided by applicant): We have recognized an urgent need for a commercially applicable high throughput way to isolate pure DNA with long and uniform fragment length for nextgen genomic s ...

    SBIRPhase I2010Department of Health and Human Services National Institutes of Health
  5. Innate Immune Protection by Clean Genome E. coli

    Amount: $139,981.00

    DESCRIPTION (provided by applicant): Complications arising from pathogen infection incur a tremendous societal cost both in morbidity and mortality (as high as 50-60%), as well as in care and treatmen ...

    SBIRPhase I2010Department of Health and Human Services National Institutes of Health
  6. Improved bacterial strains for therapeutic DNA and protein production

    Amount: $1,825,980.00

    DESCRIPTION (provided by applicant): The goal of this Phase II proposal is to evaluate Scarab Genomics' improved E. coli production strains in real world conditions under which pharmacological grade ...

    SBIRPhase II2009Department of Health and Human Services National Institutes of Health
  7. Engineered revision of the E. coli Nissle 1917 Genome

    Amount: $141,037.00

    DESCRIPTION (provided by applicant): The ability of genetically modified probiotic (beneficial) bacteria to deliver therapeutic compounds is a promising new experimental method for delivering fragile ...

    SBIRPhase I2008Department of Health and Human Services National Institutes of Health
  8. Improved bacterial strains for therapeutic DNA production

    Amount: $139,203.00

    DESCRIPTION (provided by applicant): Principal Investigator/Program Director (Last, First, Middle): Blattner, Frederick R. Abstract: The goal of this proposal is to develop methods and strains for man ...

    SBIRPhase I2007Department of Health and Human Services National Institutes of Health
  9. Clean-Genome vaccines against biodefense agents

    Amount: $1,000,000.00

    DESCRIPTION (provided by applicant): Project description: We propose to develop a new vaccine delivery platform based on a non-pathogenic E. coli with specific safety features. Compared with other ...

    SBIRPhase I2006Department of Health and Human Services National Institutes of Health
  10. Engineered Revision of E. coli for Production of DNA, Proteins and Metabolites

    Amount: $1,337,280.00

    DESCRIPTION (provided by applicant): Our goal is to improve the versatility, safety and effectiveness of E. coli as a platform for commercial production of DNA, proteins and metabolites. The natura ...

    SBIRPhase II2005Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government